BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan F, Zhao M, Xiong F, Wang Y, Zhang S, Gong Z, Li X, He Y, Shi L, Wang F, Xiang B, Zhou M, Li X, Li Y, Li G, Zeng Z, Xiong W, Guo C. N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies. J Exp Clin Cancer Res 2021;40:146. [PMID: 33926508 DOI: 10.1186/s13046-021-01952-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Ouyang J, Zhong Y, Zhang Y, Yang L, Wu P, Hou X, Xiong F, Li X, Zhang S, Gong Z, He Y, Tang Y, Zhang W, Xiang B, Zhou M, Ma J, Li Y, Li G, Zeng Z, Guo C, Xiong W. Long non-coding RNAs are involved in alternative splicing and promote cancer progression. Br J Cancer 2021. [PMID: 34750493 DOI: 10.1038/s41416-021-01600-w] [Reference Citation Analysis]
2 Kong H, Sun J, Zhang W, Zhang H, Li H. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered 2022;13:3108-21. [PMID: 35037556 DOI: 10.1080/21655979.2022.2025701] [Reference Citation Analysis]
3 Khatiwada B, Nguyen TT, Purslow JA, Venditti V. Solution structure ensemble of human obesity-associated protein FTO reveals druggable surface pockets at the interface between the N- and C-terminal domain. Journal of Biological Chemistry 2022. [DOI: 10.1016/j.jbc.2022.101907] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zou Y, Zheng S, Xie X, Ye F, Hu X, Tian Z, Yan SM, Yang L, Kong Y, Tang Y, Tian W, Xie J, Deng X, Zeng Y, Chen ZS, Tang H, Xie X. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun 2022;13:2672. [PMID: 35562334 DOI: 10.1038/s41467-022-30217-7] [Reference Citation Analysis]
5 Xiao Q, Lei L, Ren J, Peng M, Jing Y, Jiang X, Huang J, Tao Y, Lin C, Yang J, Sun M, Tang L, Wei X, Yang Z, Zhang L. Mutant NPM1-Regulated FTO-Mediated m6A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol 2022;12:817584. [PMID: 35211409 DOI: 10.3389/fonc.2022.817584] [Reference Citation Analysis]
6 Prakash M, Itoh Y, Fujiwara Y, Takahashi Y, Takada Y, Mellini P, Elboray EE, Terao M, Yamashita Y, Yamamoto C, Yamaguchi T, Kotoku M, Kitao Y, Singh R, Roy R, Obika S, Oba M, Wang DO, Suzuki T. Identification of Potent and Selective Inhibitors of Fat Mass Obesity-Associated Protein Using a Fragment-Merging Approach. J Med Chem 2021;64:15810-24. [PMID: 34727689 DOI: 10.1021/acs.jmedchem.1c01107] [Reference Citation Analysis]
7 Wang X, Lu X, Wang P, Chen Q, Xiong L, Tang M, Hong C, Lin X, Shi K, Liang L, Lin J. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner. J Transl Med 2022;20:198. [PMID: 35509101 DOI: 10.1186/s12967-022-03399-3] [Reference Citation Analysis]
8 Huang Y, Chen S, Pang L, Feng Z, Su H, Zhu W, Wei J. Isovitexin protects against acute liver injury by targeting PTEN, PI3K and BiP via modification of m6A. Eur J Pharmacol 2022;917:174749. [PMID: 35007522 DOI: 10.1016/j.ejphar.2022.174749] [Reference Citation Analysis]
9 Liu Q. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. Front Genet 2021;12:825109. [PMID: 35087575 DOI: 10.3389/fgene.2021.825109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Yang L, Chen X, Qian X, Zhang J, Wu M, Yu A. Comprehensive Analysis of the Transcriptome-Wide m6A Methylome in Endometrioid Ovarian Cancer. Front Oncol 2022;12:844613. [PMID: 35280730 DOI: 10.3389/fonc.2022.844613] [Reference Citation Analysis]
11 Wang ZW, Pan JJ, Hu JF, Zhang JQ, Huang L, Huang Y, Liao CY, Yang C, Chen ZW, Wang YD, Shen BY, Tian YF, Chen S. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Cell Rep 2022;39:110813. [PMID: 35545048 DOI: 10.1016/j.celrep.2022.110813] [Reference Citation Analysis]